Immunotherapy trials in Parkinson’s disease: challenges

Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91:795–808. Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the pipeline targeting alpha-synuclein for parkinson’s disease. Pharmacol Rev. 2022;74:207–37. Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020;16:303–18. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454–69. Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, et al. Trial of cinpanemab in early parkinson’s disease. N Engl J Med. 2022;387:408–20. Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in parkinson’s disease-like models. J Neurosci. 2014;34:9441–54. Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, et al. Trial of prasinezumab in early-stage parkinson’s disease. N Engl J Med. 2022;387:421–32. Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, et al. Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in parkinson’s disease models. Neurobiol Dis. 2019;124:276–88. Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, et al. Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054. Mov Disord. 2019;34:1154–63. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75:1206–14. Jo J, Yang L, Tran HD, Yu W, Sun AX, Chang YY, Jung BC, Lee SJ, Saw TY, Xiao B, et al. Lewy body-like inclusions in human midbrain organoids carrying glucocerebrosidase and alpha-synuclein mutations. Ann Neurol. 2021;90:490–505. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, et al. Placebo response in parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008;23:690–9. Espay AJ, Norris MM, Eliassen JC, Dwivedi A, Smith MS, Banks C, Allendorfer JB, Lang AE, Fleck DE, Linke MJ, Szaflarski JP. Placebo effect of medication cost in parkinson disease: a randomized double-blind study. Neurology. 2015;84:794–802. Agid Y. Parkinson’s disease: pathophysiology. Lancet. 1991;337:1321–4. Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB. Disease MDSTFotDoPs: update of the mds research criteria for prodromal parkinson’s disease. Mov Disord. 2019;34:1464–70. Movement Disorder Society Task Force on Rating Scales for Parkinson’s D. The unified parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–50.